PARACEST AGENTS: OPTIMIZATION FOR HUMAN MR IMAGING
PARACEST AGENTS: OPTIMIZATION FOR HUMAN MR IMAGING
批准号:
7600866
负责人:
ROBERT E LENKINSKI
金额:
$1.51万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-01 至 2008-08-31
关键词:
AddressAreaBindingChemicalsChemistryClassComputer Retrieval of Information on Scientific Projects DatabaseContrast MediaDetectionDevelopmentEnvironmentFrequenciesFundingGadoliniumGoalsGrantHumanImageIn VitroInstitutionLanthanoid Series ElementsLeadMagnetic Resonance ImagingMeasuresNumbersPerfusionPhysiologic pulsePulse takingRateResearchResearch PersonnelResourcesSignal TransductionSourceSpin LabelsUnited States National Institutes of HealthValidationWaterhuman studyin vivoirradiationresearch studysimulationtheories
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Paramagnetic chemical exchange saturation transfer (PARACEST) agents offer a potential new paradigm in MR imaging. An advantage to this class of agents is the ability to switch each agent on or off through selective RF irradiation applied at the frequency of either its bound water resonance or an exchanging NH group. This feature means that multiple, targeted PARACEST agents can be injected together and their effects imaged either sequentially or simultaneously. In their ""off"" state, i.e. when not specifically irradiated, PARACEST agents will not interfere with conventional MR imaging sequences, with or without gadolinium. In principle, PARACEST agents can be tailored to each application because their effects depend on their water exchange rates, and these rates can be modified using rational chemical principles. This feature also makes them an attractive platform for the development of responsive agents and bifunctional agents. The goal of this BRP is to realize the full potential of these compounds as contrast agents in vivo, by systematically addressing a number of basic, theoretical and practical questions. These include establishing the relationships among the magnitude of the effect measured in an imaging experiment and the water exchange lifetime, the magnitude of the chemical shift difference between the bound and bulk water, the strength of the saturating RF field, SAR, concentration, and local environment in vivo. This partnership is made up of two academic institutions and an industrial collaborator. The three main overlapping and interactive areas of focus are: lanthanide chemistry, which will be carried out at UT Dallas (UTD); Pulse sequence implementation, theory, simulations and in vitro validation which will be carried out primarily at the General Electric Global Research Center (GEGRC) and in vivo validation carried out primarily at the BIDMC. Dean Sherry (Project Leader, UTD) is an internationally recognized expert in the synthesis and characterization of lanthanide chelates. Donald Woessner (Lead Investigator, UTD), an internationally recognized expert in basic NMR exchange theory.Thomas Dixon and lleana Hancu (Project Leaders, GEGRC) are both experts in NMR and MR imaging. Robert Lenkinski (PI, BIDMC) is an NMR spectroscopist with expertise both in lanthanide agents and MR imaging. David Alsop (Lead Investigator, BIDMC) has a long track record in optimizing Arterial Spin Labeling perfusion studies, where the detection of small signal intensity changes in the presence of RF irradiation is necessary. Over the past several years, this team has been collaborating on the theoretical and practical aspects of the PARACEST effect. The successful completion of this project will result in a set of agents and MR acquisition strategies for use in human studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
OPTIMIZING PARACEST AGENTS FOR HUMAN MR IMAGING
-
批准号:8363909
-
项目类别:
-
资助金额:$1.61万
-
财政年份:2011
-
负责人:ROBERT E LENKINSKI
-
依托单位:
EXTERNAL ADVISORY COMMITTEE
-
批准号:8363922
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2011
-
负责人:ROBERT E LENKINSKI
-
依托单位:
OPTIMIZING PARACEST AGENTS FOR HUMAN MR IMAGING
-
批准号:8171660
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2010
-
负责人:ROBERT E LENKINSKI
-
依托单位:
EXTERNAL ADVISORY COMMITTEE
-
批准号:8171673
-
项目类别:
-
资助金额:$0.52万
-
财政年份:2010
-
负责人:ROBERT E LENKINSKI
-
依托单位:
OPTIMIZING PARACEST AGENTS FOR HUMAN MR IMAGING
-
批准号:7956980
-
项目类别:
-
资助金额:$1.78万
-
财政年份:2009
-
负责人:ROBERT E LENKINSKI
-
依托单位:
EXTERNAL ADVISORY COMMITTEE
-
批准号:7956997
-
项目类别:
-
资助金额:$0.89万
-
财政年份:2009
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST AGENTS: OPTIMIZATION FOR HUMAN MR IMAGING
-
批准号:7724130
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2008
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:8431760
-
项目类别:
-
资助金额:$82.82万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:7804280
-
项目类别:
-
资助金额:$98.64万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST AGENTS: OPTIMIZATION FOR HUMAN MR IMAGING
-
批准号:7357909
-
项目类别:
-
资助金额:$1.17万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:7476265
-
项目类别:
-
资助金额:$100.52万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:7125381
-
项目类别:
-
资助金额:$102.8万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:8651911
-
项目类别:
-
资助金额:$84.55万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:8053757
-
项目类别:
-
资助金额:$89.62万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:7281683
-
项目类别:
-
资助金额:$98.67万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:8250400
-
项目类别:
-
资助金额:$88.01万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
Multivoxel MRS of Human Breast Cancer at 3T.
-
批准号:6778668
-
项目类别:
-
资助金额:$34.85万
-
财政年份:2004
-
负责人:ROBERT E LENKINSKI
-
依托单位:
Multivoxel MRS of Human Breast Cancer at 3T.
-
批准号:6891291
-
项目类别:
-
资助金额:$34.85万
-
财政年份:2004
-
负责人:ROBERT E LENKINSKI
-
依托单位:
Multivoxel MRS of Human Breast Cancer at 3T.
-
批准号:7080471
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2004
-
负责人:ROBERT E LENKINSKI
-
依托单位:
MR SPECTROSCOPY OF SUSPICIOUS BREAST MASSES
-
批准号:6315086
-
项目类别:
-
资助金额:$20.51万
-
财政年份:1997
-
负责人:ROBERT E LENKINSKI
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: